- Home
- CMRC vs IMAB Comparison
CMRC vs IMAB Comparison
Compare CMRC & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRC
- IMAB
- Stock Information
- Founded
- CMRC 2009
- IMAB 2014
- Country
- CMRC United States
- IMAB United States
- Employees
- CMRC N/A
- IMAB N/A
- Industry
- CMRC
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CMRC
- IMAB Health Care
- Exchange
- CMRC Nasdaq
- IMAB Nasdaq
- Market Cap
- CMRC 391.6M
- IMAB 384.6M
- IPO Year
- CMRC 2020
- IMAB 2020
- Fundamental
- Price
- CMRC $4.75
- IMAB $4.74
- Analyst Decision
- CMRC Strong Buy
- IMAB Strong Buy
- Analyst Count
- CMRC 1
- IMAB 4
- Target Price
- CMRC $10.00
- IMAB $6.75
- AVG Volume (30 Days)
- CMRC 938.5K
- IMAB 4.8M
- Earning Date
- CMRC 07-31-2025
- IMAB 08-20-2025
- Dividend Yield
- CMRC N/A
- IMAB N/A
- EPS Growth
- CMRC N/A
- IMAB N/A
- EPS
- CMRC N/A
- IMAB N/A
- Revenue
- CMRC $337,541,000.00
- IMAB N/A
- Revenue This Year
- CMRC $5.06
- IMAB N/A
- Revenue Next Year
- CMRC $5.25
- IMAB N/A
- P/E Ratio
- CMRC N/A
- IMAB N/A
- Revenue Growth
- CMRC 4.06
- IMAB N/A
- 52 Week Low
- CMRC $4.14
- IMAB $0.60
- 52 Week High
- CMRC $7.99
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- CMRC N/A
- IMAB 59.70
- Support Level
- CMRC N/A
- IMAB $4.36
- Resistance Level
- CMRC N/A
- IMAB $5.64
- Average True Range (ATR)
- CMRC 0.00
- IMAB 0.63
- MACD
- CMRC 0.00
- IMAB -0.02
- Stochastic Oscillator
- CMRC 0.00
- IMAB 52.65
About CMRC Commerce.com Inc. Series 1 Common Stock
Commerce.com Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of its revenue is generated from Americas-U.S.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).